Nothing Special   »   [go: up one dir, main page]

BR9709223A - Estimulação dos mecanismos de defesa do hospedeiro contra tumores. - Google Patents

Estimulação dos mecanismos de defesa do hospedeiro contra tumores.

Info

Publication number
BR9709223A
BR9709223A BR9709223-1A BR9709223A BR9709223A BR 9709223 A BR9709223 A BR 9709223A BR 9709223 A BR9709223 A BR 9709223A BR 9709223 A BR9709223 A BR 9709223A
Authority
BR
Brazil
Prior art keywords
stimulation
defense mechanisms
against tumors
host
mechanisms against
Prior art date
Application number
BR9709223-1A
Other languages
English (en)
Inventor
Michael Gerard Tovey
Thomas James Kaido
Original Assignee
Pharma Pacific Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Pacific Pty Ltd filed Critical Pharma Pacific Pty Ltd
Publication of BR9709223A publication Critical patent/BR9709223A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)

Abstract

Patente de Invenção: <B>''ESTIMULAçãO DOS MECANISMOS DE DEFESA DO HOSPEDEIRO CONTRA TUMORES''<D>. Método para o tratamento de doença neoplásica em um mamífero via a administração ao mamífero de uma Quantidade terapeuticamente eficaz de um interferon via o contato oromucosal. A quantidade de interferon administrada é menos do que uma quantidade que induz uma resposta patológica quando administrado parenteralmente.
BR9709223-1A 1996-05-09 1997-05-05 Estimulação dos mecanismos de defesa do hospedeiro contra tumores. BR9709223A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPN9765A AUPN976596A0 (en) 1996-05-09 1996-05-09 Stimulation of host defence mechanisms
PCT/IB1997/000594 WO1997041886A1 (en) 1996-05-09 1997-05-05 Stimulation of host defence mechanisms against tumors

Publications (1)

Publication Number Publication Date
BR9709223A true BR9709223A (pt) 2000-12-12

Family

ID=3794078

Family Applications (2)

Application Number Title Priority Date Filing Date
BR9709066-2A BR9709066A (pt) 1996-05-09 1997-05-05 Estìmulo de mecanismos de defesa de hospedeiro contra desafios virais.
BR9709223-1A BR9709223A (pt) 1996-05-09 1997-05-05 Estimulação dos mecanismos de defesa do hospedeiro contra tumores.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR9709066-2A BR9709066A (pt) 1996-05-09 1997-05-05 Estìmulo de mecanismos de defesa de hospedeiro contra desafios virais.

Country Status (17)

Country Link
EP (2) EP0898478B1 (pt)
JP (2) JP3806444B2 (pt)
KR (2) KR100399501B1 (pt)
CN (1) CN1154508C (pt)
AR (2) AR007058A1 (pt)
AT (2) ATE316791T1 (pt)
AU (3) AUPN976596A0 (pt)
BR (2) BR9709066A (pt)
CA (2) CA2253902A1 (pt)
DE (2) DE69735204T2 (pt)
ES (2) ES2260794T3 (pt)
ID (2) ID16886A (pt)
IL (2) IL126970A0 (pt)
NZ (2) NZ332688A (pt)
TW (1) TW528599B (pt)
WO (2) WO1997041886A1 (pt)
ZA (1) ZA973988B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6299871B1 (en) * 1998-07-24 2001-10-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Orally-administrable therapeutic and/or prophylactic agent for HTLV-1-related diseases
US6710025B1 (en) 1999-05-26 2004-03-23 The Brigham And Women's Hospital, Inc. Treatment of damaged tissue using agents that modulate the activity of alpha-smooth muscle actin
WO2000071148A2 (en) * 1999-05-26 2000-11-30 The Brigham And Women's Hospital, Inc. Therapeutic uses of agents that modulate the activity of alpha-smooth muscle actin
US20040258663A1 (en) * 2003-05-08 2004-12-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon alpha
ATE374838T1 (de) 2004-04-29 2007-10-15 Hoffmann La Roche Nukleotidsequenzvariation im gen ns5a als marker
DE102007014752A1 (de) 2007-03-28 2008-10-02 Dusek, Niels, Dr. Verwendung von humanidentischem oder humanaequivalentem rekombinantem Interleukin-2 (heqlL-2) als Therapeutikum in der Human- und Veterinärmedizin

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0058192A1 (en) * 1980-08-22 1982-08-25 University of Illinois Foundation Delivery of biologically active components of heterologous species interferon isolates
US5286748A (en) * 1981-01-05 1994-02-15 Eby Iii George A General method of shortening the duration of common colds by application of medicaments to tissues of oral cavity
US4820515A (en) * 1982-12-13 1989-04-11 Texas A&M University System Method of using interferon in low dosage to regulate appetite and efficiency of food utilization
US4605555A (en) * 1984-09-20 1986-08-12 Sun Star Kabushiki Kaisha Composition and method for treating keratosic disorder of skin and mucosa
IL76591A0 (en) * 1984-10-05 1986-02-28 Bioferon Biochem Substanz Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof
ZA878295B (en) * 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
JP2704546B2 (ja) * 1989-04-04 1998-01-26 光利 太良 Ａｔｌｌ治療用吸入剤
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5215741A (en) * 1990-10-30 1993-06-01 Amarillo Cell Culture Company, Incorporated Method for prevention of parasite infections
WO1992010207A1 (en) * 1990-12-14 1992-06-25 Schering Corporation Oral administration of alpha interferon to treat lung malignancies
US5780021A (en) * 1993-03-05 1998-07-14 Georgetown University Method for treating type 1 diabetes using α-interferon and/or β-i
IL113280A (en) * 1994-04-12 2004-12-15 Res Dev Foundation A preparation for the treatment of self-immunization diseases with the help of interferon of one type
IL126971A0 (en) * 1996-05-09 1999-09-22 Pharma Pacific Pty Ltd Interferon compositions

Also Published As

Publication number Publication date
DE69735201T2 (de) 2006-09-21
NZ332690A (en) 2000-07-28
ES2260790T3 (es) 2006-11-01
AU729514B2 (en) 2001-02-01
AUPN976596A0 (en) 1996-05-30
CA2253908A1 (en) 1997-11-13
EP0898478A1 (en) 1999-03-03
ES2260794T3 (es) 2006-11-01
KR100399499B1 (ko) 2003-12-18
JP3806446B2 (ja) 2006-08-09
DE69735204T2 (de) 2006-09-21
JP2000504027A (ja) 2000-04-04
AR007058A1 (es) 1999-10-13
EP0956040B1 (en) 2006-02-01
EP0956040A4 (pt) 1999-11-17
ZA973988B (en) 1998-11-09
AU2710997A (en) 1997-11-26
JP2000504026A (ja) 2000-04-04
CN1154508C (zh) 2004-06-23
WO1997041886A1 (en) 1997-11-13
EP0898478A4 (en) 1999-05-26
JP3806444B2 (ja) 2006-08-09
ID16886A (id) 1997-11-20
KR100399501B1 (ko) 2003-12-18
CN1218409A (zh) 1999-06-02
EP0898478B1 (en) 2006-02-01
AU724190B2 (en) 2000-09-14
IL126970A0 (en) 1999-09-22
DE69735204D1 (de) 2006-04-13
KR20000010880A (ko) 2000-02-25
NZ332688A (en) 2000-07-28
ATE316793T1 (de) 2006-02-15
ID16885A (id) 1997-11-20
DE69735201D1 (de) 2006-04-13
IL126972A0 (en) 1999-09-22
WO1997041883A1 (en) 1997-11-13
ATE316791T1 (de) 2006-02-15
KR20000010882A (ko) 2000-02-25
TW528599B (en) 2003-04-21
AU2399297A (en) 1997-11-26
CA2253902A1 (en) 1997-11-13
EP0956040A1 (en) 1999-11-17
AR007059A1 (es) 1999-10-13
BR9709066A (pt) 2000-01-04

Similar Documents

Publication Publication Date Title
ATE316792T1 (de) Stimulierung wirtseigener abwehrmechanismen gegen krebs
ES2162615T3 (es) Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina.
GEP20002142B (en) Method for Treatment and Prevention of TNF Mediated Diseases
DK0850068T3 (da) Lipidekstrakt med antiinflammatorisk aktivitet
ATE522211T1 (de) Stabilisierte fibrat-mikropartikel
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
BR9607212A (pt) Uso de uma nsaid-r em uma composição de proteção para o tratamento de cancer de colo retal
PT814784E (pt) Utilizacao de farmacos anti-inflamatorios nao esteroides (nsaids) para o tratamento de carcinomas das celulas escamosas da cavidade oral ou orofaringea
KR970704429A (ko) 심혈관 질환의 치료를 위한 드롤록시펜의 용도(use of droloxifene for the treatment of cardiovascular diseases)
IL124977A0 (en) Oral administration of effective amounts of forms of hyaluronic acid
DE60127457D1 (de) Fibrat-statin kombinationen mit verminderten von der nahrungsaufnahme abhängigen auswirkungen
BR9807577A (pt) Método para prevenir e retardar o inìcio da doença de alzheimer e sua composição
KR960703009A (ko) 중추유래의 수면성 무호흡증 및 호흡곤란증의 치료를 위한 모다피닐의 사용
KR950700749A (ko) 2&#39;-할로메틸리덴 유도체와 S-기 또는 M-기 특이성 항종양제를 사용하는 결합치료에 의한 암치료 방법(Method of treating cancer by conjunctive therapy with 2&#39;-halomethylidene derivatives and a S-phase or M phase specific antineoplastic agent)
BR0211336A (pt) Métodos para o tratamento da fibrose do fìgado
EP0957925A4 (en) TREATMENT OF OSTEOARTHRITIS BY ADMINISTRATION OF POLY-N-ACETYL-D-GLUCOSAMINE
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
BR9709223A (pt) Estimulação dos mecanismos de defesa do hospedeiro contra tumores.
ES2136167T3 (es) Composiciones de idebenona para tratar la enfermedad de alzheimer.
CA2150183A1 (en) Pharmaceutical composition for the treatment of hemorrhoidal diseases
BR9809673A (pt) Derivados de triptolida úteis no tratamento de doenças autoimunes
BR0311613A (pt) Métodos para inibição, tratamento ou prevenção de sintomas de atrofia da pele, ou atrofia epitelial ou da mucosa nas mulheres e utilização de composto
BR9907234A (pt) Polìmeros ligantes de gordura
ES2101311T3 (es) Utilizacion de un dispositivo transdermico que contiene (e)-2-(p-fluorofenetil)-3-fluoroalilamina y su uso para el tratamiento de la enfermedad de alzheimer.
KR910009255A (ko) 과트리글리세라이드혈증과, 콜레스테롤혈증, 저레벨의 hdl질환 및 아테롬성 동맥경화증 치료제로서 사용되는 2-(페녹시 프로파놀아미노)에톡시 페녹시아세트산 유도체

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]